No. of patients | 28 (41%) | 41 (59%) | – |
Women:men | 20:8 | 39:2 | 0.0060* |
Time of disease (months) | 19.8 | 232.5 | 0.0001* |
NP manifestations at onset | 7 (25%) | 11 (27%) | 0.8651 |
Time from diagnosis to NP manifestation (months) | 42.4 | 87.1 | 0.1268 |
Lupus nephritis | 16 (57%) | 9 (22%) | 0.0028* |
Antiphospholipid syndrome | 5 (18%) | 10 (24%) | 0.5182 |
ANA ≥1/1280 | 8 (29%) | 11 (27%) | 0.8736 |
Anti-DNA ab (IU/ml) | 178.9 | 39.4 | 0.0005* |
Anti-Ro/SSA ab | 10 (36%) | 17 (41%) | 0.6308 |
Anticardiolipin ab | 4 (14%) | 10 (24%) | 0.3054 |
Anti-ß2 glycopotein I ab | 5 (18%) | 7 (17%) | 0.9328 |
Lupus anticoagulant | 8 (29%) | 10 (24%) | 0.6977 |
Cryoglobulins | 6 (21%) | 3 (7%) | 0.0874 |
ESR (mm/h) | 53.8 | 35.7 | 0.0199* |
CRP mg/l | 4.6 | 4.7 | 0.9687 |
C3 low (<80 mg/dl) | 22 (79%) | 16 (39%) | 0.0012* |
C4 low (<16 mg/dl) | 22 (79%) | 13 (32%) | 0.0001* |